A Randomized, Placebo-controlled, Double-blind, Proof-of-concept Study of Intravenous Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Syndrome
Latest Information Update: 13 Jun 2016
At a glance
- Drugs Canakinumab (Primary) ; Secukinumab (Primary)
- Indications Dry eyes
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
Most Recent Events
- 18 Dec 2014 New trial record